Xilio Therapeutics annual operating expenses
2020
2021
2022
2023
2024
2025
Xilio Therapeutics Operating Expenses Growth & History (XLO)
Xilio Therapeutics's operating expenses was $85.7M for fiscal 2025.
View full Xilio Therapeutics company overviewXilio Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $85.7M | $18.8M | +28.12% |
| 2024 | 2024-12-31 | $66.9M | −$12.2M | −15.43% |
| 2023 | 2023-12-31 | $79.1M | −$10.0M | −11.24% |
| 2022 | 2022-12-31 | $89.1M | $14.1M | +18.80% |
| 2021 | 2021-12-31 | $75.0M | $20.5M | +37.54% |
| 2020 | 2020-12-31 | $54.6M | — | — |
Xilio Therapeutics quarterly operating expenses
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $22.2M | −$267,000 | −1.19% |
| Q1 2026 | 2026-03-31 | $26.8M | $10.0M | +59.47% |
| Q4 2025 | 2025-12-31 | $25.5M | $10.2M | +66.23% |
| Q3 2025 | 2025-09-30 | $21.0M | $4.0M | +23.32% |
| Q2 2025 | 2025-06-30 | $22.4M | $5.4M | +31.59% |
| Q1 2025 | 2025-03-31 | $16.8M | −$706,000 | −4.04% |
| Q4 2024 | 2024-12-31 | $15.4M | −$2.8M | −15.32% |
| Q3 2024 | 2024-09-30 | $17.0M | −$336,000 | −1.94% |
| Q2 2024 | 2024-06-30 | $17.1M | −$3.1M | −15.19% |
| Q1 2024 | 2024-03-31 | $17.5M | −$6.0M | −25.67% |
| Q4 2023 | 2023-12-31 | $18.1M | −$5.0M | −21.74% |
| Q3 2023 | 2023-09-30 | $17.4M | −$2.8M | −14.08% |
| Q2 2023 | 2023-06-30 | $20.1M | −$4.4M | −18.07% |
| Q1 2023 | 2023-03-31 | $23.5M | $2.3M | +10.85% |
| Q4 2022 | 2022-12-31 | $23.2M | $3.6M | +18.46% |
| Q3 2022 | 2022-09-30 | $20.2M | $4.2M | +26.60% |
| Q2 2022 | 2022-06-30 | $24.6M | $1.5M | +6.72% |
| Q1 2022 | 2022-03-31 | $21.2M | $4.7M | +28.47% |
| Q4 2021 | 2021-12-31 | $19.6M | — | — |
| Q3 2021 | 2021-09-30 | $16.0M | $1.3M | +9.15% |
| Q2 2021 | 2021-06-30 | $23.0M | — | — |
| Q1 2021 | 2021-03-31 | $16.5M | — | — |
| Q3 2020 | 2020-09-30 | $14.6M | — | — |
Xilio Therapeutics operating expenses trends
Over the last five fiscal years, Xilio Therapeutics's operating expenses increased from $54.6M to $85.7M, a change of $31.2M. The latest reported quarter, Q2 2026, shows $22.2M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xilio Therapeutics source filings ↗